NHS England has recommended fampridine for routine use in adults with multiple sclerosis (MS), improving access to the only licensed medicine shown to enhance walking ability in eligible patients. The decision, announced on 17 July 2026, follows years of campaigning and is expected to broaden access as generic versions become available after the expiry of…
Pair of studies explores menopause’s role in multiple sclerosis progression
Two new research projects are investigating whether the hormonal and biological changes associated with menopause influence the progression of multiple sclerosis (MS), with the aim of helping clinicians deliver more personalised care for women during midlife. Funded by the National Multiple Sclerosis Society, the complementary studies will examine both the biological changes linked to reproductive…
Study finds little to no cortical Lewy pathology in Parkinson’s patients undergoing deep brain stimulation
Researchers at the Icahn School of Medicine at Mount Sinai have reported findings that challenge long-held assumptions about how Parkinson’s disease progresses. In a study of living patients undergoing deep brain stimulation (DBS), investigators found little to no evidence of cortical Lewy pathology in the prefrontal cortex, despite many participants having lived with clinically advanced…
Brain mapping study could improve personalised treatment for drug-resistant epilepsy
Researchers at Mayo Clinic have developed a detailed map of a deep brain structure that could help improve the precision of brain stimulation therapies for people with drug-resistant epilepsy. The study, published in the Journal of Neuroscience, focuses on the pulvinar, part of the thalamus, which plays a key role in processing and coordinating information…
FDA approves at-home subcutaneous lecanemab initiation for early Alzheimer’s disease
The US Food and Drug Administration (FDA) has approved a supplemental biologics licence application for LEQEMBI IQLIK (lecanemab-irmb) as a once-weekly subcutaneous initiation treatment for adults with early Alzheimer’s disease. The decision makes LEQEMBI IQLIK the first anti-amyloid therapy approved for both initiation and maintenance dosing at home using an autoinjector in the United States….
Blood test could improve early detection of Alzheimer’s disease, study suggests
A novel blood test based on circular RNA biomarkers could improve the early detection of Alzheimer’s disease and identify people at risk years before symptoms develop, according to research published in Nature Medicine and highlighted by biotechnology company Circular Genomics. The study analysed almost 2,400 participants across three independent cohorts and found that a blood-based…
First view of alpha-synuclein pathology in the living brain
Researchers have reported the first successful visualisation of pathological alpha-synuclein aggregates in the living human brain using a novel positron emission tomography (PET) tracer, a development that could transform the diagnosis and monitoring of Parkinson’s disease and related neurodegenerative disorders. The study, published in Science Translational Medicine, describes the development and validation of [11C]MODAG-005, a…
Briumvi beats Aubagio as first MS treatment in ULTIMATE trial analysis
Briumvi led to fewer relapses, less MRI activity and better disability improvement than Aubagio when used as the first disease-modifying therapy for relapsing multiple sclerosis, according to a new post-hoc analysis of the phase 3 ULTIMATE I and II trials. The analysis focused on 722 participants who had not previously received an approved disease-modifying therapy,…
Women with Parkinson’s may have more Alzheimer’s-related brain changes than men, study suggests
Women with Parkinson’s disease may be more likely than men to show Alzheimer’s-related changes in the brain, according to research presented at the European Academy of Neurology Congress 2026. The study, led by researchers at Mayo Clinic Arizona, examined 230 autopsy-confirmed cases of Parkinson’s disease from the Arizona Study of Aging and Neurodegenerative Disorders and…
Multiple sclerosis affects social life and work as much as physical health, study finds
Multiple sclerosis can affect far more than a person’s physical health, with new research suggesting that social life, employment, finances and education are all commonly disrupted by the condition. The findings were presented at the European Academy of Neurology Congress 2026 and come from the SocialMS study, a nationwide Italian survey involving 1,039 adults with…
